The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Virginia Patent Foundation

Adrian U Wiestner

Wyndham H Wilson

Louis M Staudt

Andreas Rosenwald

Todd S Barry

Christoph Rader

Ronald P Taylor

Margaret A Lindorfer

Berengere Vire

Yihong Ye

William Trenkle

Martin W Skarzynski

Qiuyan Wang

Helena Mora-Jensen

Bidhan A Shinkre

Wyndham Wilson

Bérengère Vire

An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.

Antibody targeting cell surface deposited complement protein C3d and use thereof

It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.

ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)

The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.

Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment

Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.

Hydrazone and diacyl hydrazine compounds and methods of use

It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.

ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Growing community of inventors

Bethesda, MD, United States of America

Adrian U Wiestner